Among adults with type 2 diabetes, SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases compared with sulfonylureas.

I am a 68-year-old woman who is in relatively good health. My primary exercise is walking my dogs anywhere from 2-5 miles per day. I have two ...

Q: I’m slated to retire next year, and it scares me to death — well, I hope not death, exactly, but I’m not sure what to do ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

Eli Lilly announces positive results from phase 3 ACHIEVE-2 & ACHIEVE-5 trials of orforglipron versus dapagliflozin in adults with type 2 diabetes: Indianapolis Thursday, October ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

Health technology assessment (HTA) has long been associated with the adoption and evaluation of innovations and new technologies. The current HTA definition includes the concept of ‘determining the ...

Prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors for ambulatory patients with heart failure (HF) has increased significantly in recent years. However, several subgroups, including ...